Cyclo Therapeutics Company Overview
About Cyclo Therapeutics
Cyclo Therapeutics (NASDAQ:CYTH) is a biotechnology company focused on the development of innovative therapies for diseases with a critical need for treatment options. The firm is dedicated to advancing its lead product candidate, Trappsol® Cyclo™, through clinical trials for the treatment of Niemann-Pick Disease Type C, a rare genetic disorder. Additionally, Cyclo Therapeutics is exploring the potential of its proprietary technology in other therapeutic areas, aiming to leverage its cyclodextrin-based drug delivery platform to improve the efficacy and safety of various treatments. With a commitment to scientific excellence and patient care, the company's objectives include advancing its research and development programs, securing regulatory approvals, and pursuing strategic partnerships to enhance its product pipeline and address unmet medical needs.
Snapshot
Operations
Produtos e/ou serviços de Cyclo Therapeutics
- Trappsol Cyclo for Niemann-Pick Disease Type C, a cholesterol-clearing treatment in clinical trials.
- Cyclodextrin-based products aimed at rare and serious diseases, leveraging proprietary technology for improving drug solubility and delivery.
- Collaboration on advanced drug delivery systems targeting improved efficacy and reduced side effects for existing medications.
- Development of non-invasive diagnostics tools for early detection and monitoring of chronic diseases.
- Research partnerships focused on gene therapy vectors, enhancing the delivery and safety of genetic treatments.
- Licensing agreements for the use of its cyclodextrin-based technologies in pharmaceutical and biotechnological applications.
equipe executiva do Cyclo Therapeutics
- Mr. N. Scott FineCEO & Director
- Mr. C. E StrattanFounder & Director
- Mr. Joshua M. FineCFO & Secretary
- Mr. Michael Eric LisjakSenior VP of Business Development & Chief Regulatory Officer
- Dr. Jeffrey L. Tate Ph.D.COO, Chief Quality Officer & Director
- Ms. Lori McKennaGlobal Head of Patient Advocacy
- Dr. Karen Mullen FFPMInterim Chief Medical Officer